Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves.
Here, we show that extracorporeal shock waves (ESW), at a low energy density value, quickly increase neuronal nitric oxide synthase (nNOS) activity and basal nitric oxide (NO) production in the rat glioma cell line C6. In addition, the treatment of C6 cells with ESW reverts the decrease of nNOS activity and NO production induced by a mixture of lipopolysaccharides (LPS), interferon-gamma (IFN-gamma) plus tumour necrosis factor-alpha (TNF-alpha). Finally, ESW treatment efficiently downregulates NF-kappaB activation and NF-kappaB-dependent gene expression, including inducible NOS and TNF-alpha. The present report suggests a possible molecular mechanism of the anti-inflammatory action of ESW treatment.
Ciampa
Anna R
AR
Dipartimento di Scienze Neurologiche e della Visione, Sezione di Chimica Biologica, Università degli Studi di Verona, Strada Le Grazie, 8, 37134 Verona, Italy.
de Prati
Alessandra Carcereri
AC
Amelio
Ernesto
E
Cavalieri
Elisabetta
E
Persichini
Tiziana
T
Colasanti
Marco
M
Musci
Giovanni
G
Marlinghaus
Ernst
E
Suzuki
Hisanori
H
Mariotto
Sofia
S
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D045424:Complex Mixtures / Q000494:pharmacology; D024202:Electrophoretic Mobility Shift Assay; D015971:Gene Expression Regulation, Enzymologic / Q000528:radiation effects*; D005910:Glioma / Q000737:chemistry / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D019220:High-Energy Shock Waves / Q000627:therapeutic use*; D007249:Inflammation / Q000628:therapy*; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D018613:Microscopy, Confocal; D009474:Neurons / Q000201:enzymology / Q000378:metabolism; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D051381:Rats; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D045424:Complex Mixtures; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha; D009569:Nitric Oxide; D007371:Interferon-gamma; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II